These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11397121)

  • 41. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6).
    Cho HJ; Caballero OL; Gnjatic S; Andrade VC; Colleoni GW; Vettore AL; Outtz HH; Fortunato S; Altorki N; Ferrera CA; Chua R; Jungbluth AA; Chen YT; Old LJ; Simpson AJ
    Cancer Immun; 2006 Dec; 6():12. PubMed ID: 17137291
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy.
    Napoletano C; Bellati F; Tarquini E; Tomao F; Taurino F; Spagnoli G; Rughetti A; Muzii L; Nuti M; Benedetti Panici P
    Am J Obstet Gynecol; 2008 Jan; 198(1):99.e1-7. PubMed ID: 18166319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression in childhood primary brain tumors of NY-ESO-1, a cancer/testis antigen: an immunohistochemical study.
    Bodey B; Bodey V; Siegel SE
    In Vivo; 2008; 22(1):83-7. PubMed ID: 18396787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Expression of NY-ESO-1 gene in human esophageal carcinoma and its cloning].
    Peng LP; Liu HY; Ran YL; Sun LX; Yu L; Yang ZH
    Ai Zheng; 2002 May; 21(5):469-72. PubMed ID: 12452034
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue.
    Hudolin T; Juretic A; Spagnoli GC; Pasini J; Bandic D; Heberer M; Kosicek M; Cacic M
    Prostate; 2006 Jan; 66(1):13-8. PubMed ID: 16114059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
    Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of cancer-testis antigen (CTA) genes in intrahepatic cholangiocarcinoma.
    Utsunomiya T; Inoue H; Tanaka F; Yamaguchi H; Ohta M; Okamoto M; Mimori K; Mori M
    Ann Surg Oncol; 2004 Oct; 11(10):934-40. PubMed ID: 15466353
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The expression of 11 cancer/testis (CT) antigen genes in esophageal carcinoma].
    Liang Z; Sun ZY; Yuan YH; Han Y; Wang Y; Gu J; Zhang LJ
    Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):534-7. PubMed ID: 16438850
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters.
    Peng JR; Chen HS; Mou DC; Cao J; Cong X; Qin LL; Wei L; Leng XS; Wang Y; Chen WF
    Cancer Lett; 2005 Mar; 219(2):223-32. PubMed ID: 15723723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
    Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma.
    Syed ON; Mandigo CE; Killory BD; Canoll P; Bruce JN
    J Clin Neurosci; 2012 Jul; 19(7):1016-21. PubMed ID: 22534618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression.
    Cronwright G; Le Blanc K; Götherström C; Darcy P; Ehnman M; Brodin B
    Cancer Res; 2005 Mar; 65(6):2207-15. PubMed ID: 15781633
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential target antigens for immunotherapy in human pancreatic cancer.
    Schmitz-Winnenthal FH; Galindo-Escobedo LV; Rimoldi D; Geng W; Romero P; Koch M; Weitz J; Krempien R; Niethammer AG; Beckhove P; Buchler MW; Z'graggen K
    Cancer Lett; 2007 Jul; 252(2):290-8. PubMed ID: 17320278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer.
    Gure AO; Chua R; Williamson B; Gonen M; Ferrera CA; Gnjatic S; Ritter G; Simpson AJ; Chen YT; Old LJ; Altorki NK
    Clin Cancer Res; 2005 Nov; 11(22):8055-62. PubMed ID: 16299236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of messenger RNA of beta 1-->4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma.
    Kuo CT; Bostick PJ; Irie RF; Morton DL; Conrad AJ; Hoon DS
    Clin Cancer Res; 1998 Feb; 4(2):411-8. PubMed ID: 9516930
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
    Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M
    J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Melanoma or not? Cancer testis antigens may help.
    Lüftl M; Schuler G; Jungbluth AA
    Br J Dermatol; 2004 Dec; 151(6):1213-8. PubMed ID: 15606517
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.
    Dhodapkar MV; Osman K; Teruya-Feldstein J; Filippa D; Hedvat CV; Iversen K; Kolb D; Geller MD; Hassoun H; Kewalramani T; Comenzo RL; Coplan K; Chen YT; Jungbluth AA
    Cancer Immun; 2003 Jul; 3():9. PubMed ID: 12875607
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer.
    Nakada T; Noguchi Y; Satoh S; Ono T; Saika T; Kurashige T; Gnjatic S; Ritter G; Chen YT; Stockert E; Nasu Y; Tsushima T; Kumon H; Old LJ; Nakayama E
    Cancer Immun; 2003 Jul; 3():10. PubMed ID: 12889868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.